Overcoming erlotinib resistance with tailored treatment regimen in patient‐derived xenografts from naïve Asian NSCLC patients

Abstract excerpt

Overall benefits of EGFR-TKIs are limited because these treatments are largely only for adenocarcinoma (ADC) with EGFR activating mutation. The treatments also usually lead to development of resistances. We have established a panel of patient-derived xenografts (PDXs) from treatment naïve Asian NSCLC patients, including those containing "classic" EGFR activating mutations. Some of these EGFR-mutated PDXs do not...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lung Cancer Research Studies
• Share to Lung Cancer Treatments and Mutations
• Share to Pancreatic and Hepatic Oncology Research